OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel in vitro diagnostic test designed to detect bacterial nucleic acids; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. It also provides Acuitas MDRO Gene Test, Acuitas CR Elite Test, and Acuitas Resistome Test that are CLIA lab-based tests, which provide a profile of MDRO resistant genes for surveillance and response to outbreaks. In addition, the company offers Acuitas Lighthouse bioinformatics systems, which are cloud-based HIPAA compliant bioinformatics offerings that combine clinical lab test results with patient and hospital information, and provide analytics to enable manage MDROs in the hospital and patient care environment. Further, it engages in the development of Acuitas Rapid Test designed to detect urinary tract infection. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OPGN
CUSIPN/A
Phone240-813-1260
Debt
Debt-to-Equity Ratio0.03
Current Ratio2.45
Quick Ratio2.35
Price-To-Earnings
Trailing P/E Ratio-0.21
Forward P/E Ratio-0.87
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.21 million
Price / Sales3.86
Cash FlowN/A
Price / CashN/A
Book Value$0.62 per share
Price / Book3.35
Profitability
EPS (Most Recent Fiscal Year)($9.78)
Net Income$-15,410,000.00
Net Margins-409.83%
Return on Equity-437.11%
Return on Assets-152.04%
Miscellaneous
Employees43
Outstanding Shares5,960,000
OpGen (NASDAQ:OPGN) Frequently Asked Questions
What is OpGen's stock symbol?
OpGen trades on the NASDAQ under the ticker symbol "OPGN."
When did OpGen's stock split? How did OpGen's stock split work?
OpGen shares reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.
How were OpGen's earnings last quarter?
OpGen Inc (NASDAQ:OPGN) posted its quarterly earnings data on Tuesday, May, 8th. The medical research company reported ($0.75) earnings per share for the quarter, topping analysts' consensus estimates of ($0.84) by $0.09. The medical research company had revenue of $0.85 million for the quarter, compared to analysts' expectations of $0.74 million. OpGen had a negative net margin of 409.83% and a negative return on equity of 437.11%. View OpGen's Earnings History.
When is OpGen's next earnings date?
What price target have analysts set for OPGN?
2 Wall Street analysts have issued 1-year target prices for OpGen's stock. Their predictions range from $9.00 to $9.00. On average, they expect OpGen's share price to reach $9.00 in the next twelve months. View Analyst Ratings for OpGen.
Who are some of OpGen's key competitors?
Some companies that are related to OpGen include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), ELEKTA AB/ADR (EKTAY), Foundation Medicine (FMI), Genomic Health (GHDX), Natera (NTRA), RadNet (RDNT), CareDx (CDNA), InVitae (NVTA), Veracyte (VCYT), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Celcuity (CELC), PotNetwork (POTN) and Psychemedics (PMD).
Who are OpGen's key executives?
OpGen's management team includes the folowing people:
- Mr. Evan Jones, Chairman & CEO (Age 61)
- Mr. Timothy C. Dec, CFO, Principal Accounting Officer & Corp. Sec. (Age 59)
- Mr. Vadim Sapiro, Chief Information Officer (Age 47)
- Dr. G. Terrance Walker Ph.D., Sr. VP of R&D (Age 59)
- Mr. Michael Farmer, Director of Marketing
When did OpGen IPO?
(OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.
Has OpGen been receiving favorable news coverage?
Media stories about OPGN stock have trended somewhat positive this week, according to Accern. Accern identifies negative and positive news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OpGen earned a daily sentiment score of 0.17 on Accern's scale. They also gave media headlines about the medical research company an impact score of 47.14 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of OpGen?
Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OpGen's stock price today?
One share of OPGN stock can currently be purchased for approximately $2.08.
How big of a company is OpGen?
OpGen has a market capitalization of $13.36 million and generates $3.21 million in revenue each year. The medical research company earns $-15,410,000.00 in net income (profit) each year or ($9.78) on an earnings per share basis. OpGen employs 43 workers across the globe.
How can I contact OpGen?
OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]
MarketBeat Community Rating for OpGen (OPGN)
MarketBeat's community ratings are surveys of what our community members think about OpGen and other stocks. Vote "Outperform" if you believe OPGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
